CTX310 Lipid Disorder: Phase 1 Trial Shows Prom...

By HEOR Staff Writer

November 10, 2025

CTX310 Breakthrough in Lipid Disorder Treatment CTX310 is a significant advancement as the first-in-human Phase 1 trial of this
Eloralintide Obesity Treatment: Phase 2 Trial Reveals Significant Weight Loss...
Addressing GLP-1 Access Inequity: Lessons from HIV/AIDS Mobilization
Insights on GLP-1 Therapy in Bariatric Surgery Patients
Collaboration Cardiac Surgery: Boosting Surgical Volumes Through Multidiscipl...
AMALFI Trial: How Patch-Based ECG Monitoring Could Transform Remote Atrial Fi...
TAVI Cost-Effectiveness in Brazil: Balancing Coverage Expansion and Economic ...
Evolving Strategies in Type 2 Diabetes Management: NICE Guideline Update 2025
Guiding the Future of Digital Cardiac Rehabilitation: NICE’s Conditiona...
Cell Therapy for Type 1 Diabetes: Vertex Trial Results and Market Potential
How Gene-Editing Therapies Are Revolutionizing ASCVD Treatment and Market Tra...
Mavyret Acute Hepatitis C: Pioneering Treatment Expansion and Economic Implic...
Business Dynamics: How Novo Nordisk Lost GLP-1 Market Share